# Global Health Investment Fund (GHIF)

> Pioneer del social impact investing nella global health

## Executive Summary

| Metrica | Valore |
|---------|--------|
| **Fondazione** | 2012 |
| **Sede** | New York, USA |
| **Tipo** | Social Impact Investment Fund |
| **Management** | Global Health Investment Corporation (GHIC) |
| **AUM** | $108 milioni |
| **Status** | active (portfolio exited) |

---

## Glossario

| Termine | Definizione |
|---------|-------------|
| Social Impact Bond | Strumento finanziario che lega rendimenti a risultati sociali misurabili |
| Volume Guarantee | Garanzia di acquisto che riduce il rischio per gli investitori |
| Priority Review Voucher | Voucher FDA che accelera l'approvazione di farmaci, vendibile sul mercato |
| Dual-market product | Prodotto con mercato sia nei paesi sviluppati che in via di sviluppo |

---

## Fondazione e Storia

| Dato | Dettaglio |
|------|-----------|
| **Fondazione** | 2012 |
| **Strutturatori** | JPMorgan Chase, Bill & Melinda Gates Foundation |
| **Contesto** | Gap di finanziamento per R&D su malattie dei paesi poveri |
| **Obiettivo dichiarato** | Mobilitare capitale privato per sviluppo farmaci, vaccini e diagnostici per malattie neglette |

### Timeline Storica

| Anno | Evento |
|------|--------|
| **2012** | Lancio con $108M, strutturato da JPMorgan e Gates Foundation |
| **2012-2020** | Investimenti in 12 portfolio companies |
| **2021** | GHIC espande missione a global health security, Labeeb Abboud diventa CEO |
| **2021** | Partnership decennale con BARDA (US biodefense) |
| **2023** | Exit del fondo; prodotti portfolio raggiungono 500M+ persone |

---

## Struttura e Governance

### Organizzazione

GHIF e' gestito da **Global Health Investment Corporation (GHIC)**, non-profit indipendente fondata nel 2012.

| Entita' | Ruolo |
|---------|-------|
| GHIC | Fund manager, investment decisions |
| Lion's Head Global Partners | Asset management, portfolio origination |

### Leadership GHIC

| Ruolo | Nome | Dal |
|-------|------|-----|
| Chairman & CEO | [Labeeb M. Abboud](../persons/labeeb-abboud.md) | 2014 (Chairman), 2021 (CEO) |
| Chief Investment Officer | [Vidya Vasu-Devan](../persons/vidya-vasu-devan.md) | - |

### Board of Directors

| Nome | Background |
|------|------------|
| Labeeb M. Abboud | Ex-IAVI (17 anni), Georgetown Law |
| Paul Klingenstein | Aberdare Ventures founder, IAVI board |
| [George W. Wellde Jr.](../persons/george-wellde.md) | Goldman Sachs (30 anni), Gavi founding board, CFR |
| Arlina Elmiger | KfW Development Bank |

### Senior Advisors

| Nome | Background |
|------|------------|
| [Seth Berkley](../persons/seth-berkley.md) | Ex-CEO Gavi (2011-2023), fondatore IAVI |
| Luciana Borio | ARCH Ventures, ex-FDA, ex-NSC biodefense |
| Emilio Emini | CEO Gates Medical Research Institute, ex-Merck/Pfizer |

---

## Investitori

### Anchor Investors (2012)

| Investitore | Tipo | Note |
|-------------|------|------|
| [Gates Foundation](../foundation/gates-foundation.md) | Foundation | Co-founder, volume guarantee |
| [JPMorgan Chase](../bank/jp-morgan.md) | Bank | Fund structurer, Social Finance investor |
| [Children's Investment Fund Foundation](../foundation/ciff.md) | Foundation | Anchor investor |
| Grand Challenges Canada | Agency | Anchor, funded by Government of Canada |
| [KfW Development Bank](../bank/kfw.md) | Bank | Anchor, per conto di BMZ (Germania) |
| Swedish International Development Agency | Agency | - |

### Corporate Investors

| Investitore | Tipo |
|-------------|------|
| [GSK](../pharma/gsk.md) | Pharma |
| [Merck](../pharma/merck.md) | Pharma |
| [Pfizer](../pharma/pfizer.md) | Pharma |
| [IFC](../bank/ifc.md) | Development Bank |
| AXA Investment Managers | Asset Manager |
| Storebrand | Insurance/Asset Manager |

---

## Portfolio Companies (12)

| Company | Settore | Target |
|---------|---------|--------|
| Access Bio | Diagnostics | HIV, malaria |
| Alydia Health | Device | Maternal health |
| Atomo Diagnostics | Diagnostics | HIV self-testing |
| BD | Diagnostics | TB, malaria |
| EUBiologics | Vaccine | Cholera |
| Genedrive | Diagnostics | TB, HCV |
| IanTech | Device | Surgical (preeclampsia) |
| Moxidectin | Treatment | River blindness |
| PATH | Treatment | Various |
| Serum Institute | Vaccine/Therapeutics | Multiple |
| Themis Bioscience | Vaccine platform | Chikungunya, COVID-19 |
| Univercells | Biologics manufacturing | Cost reduction |

### Impact

- **12+ prodotti** commercializzati
- **500+ milioni di persone** raggiunte
- Focus: HIV/AIDS, malaria, TB, cholera, river blindness, maternal health

---

## Modello di Investimento

### Strutture utilizzate

- Mezzanine debt
- Convertible debt
- Preferred equity
- Project financing

### Target per investimento

~$10 milioni per progetto

### Innovazione chiave

**Volume Guarantee**: Gates Foundation garantisce l'acquisto di prodotti a prezzi concordati, riducendo il rischio per investitori privati e incentivando R&D su malattie neglette.

---

## Connessioni PowerLink

### Network Global Health

| Organizzazione | Connessione |
|----------------|-------------|
| [Gates Foundation](../foundation/gates-foundation.md) | Co-founder, anchor investor |
| [Gavi](../agency/gavi.md) | George Wellde founding board; Seth Berkley ex-CEO |
| [IAVI](../agency/iavi.md) | Seth Berkley founder; Abboud 17 anni; multiple GHIC team |
| [CEPI](../agency/cepi.md) | Pandemic preparedness ecosystem |
| BARDA | 10-year venture partnership dal 2021 |

### Figure chiave

| Persona | Connessione |
|---------|-------------|
| [Seth Berkley](../persons/seth-berkley.md) | Senior Advisor, fonda IAVI, ex-CEO Gavi |
| [George Wellde](../persons/george-wellde.md) | Board, Goldman Sachs partner, Gavi founder |
| [Vidya Vasu-Devan](../persons/vidya-vasu-devan.md) | CIO, ex-Gates Foundation SIF ($2.5B) |

### Revolving Door Pattern

```
IAVI → GHIC: Abboud, multiple team members
Gates Foundation → GHIC: Vasu-Devan, funding
Goldman Sachs → GHIC: Wellde (board), Vasu-Devan (analyst)
Gavi ↔ GHIC: Berkley (advisor), Wellde (founding board)
```

---

## Critiche

| Tema | Dettaglio |
|------|-----------|
| Rendimenti vs Impact | Tensione strutturale tra obiettivi finanziari e sanitari |
| Dual-market focus | Priorita' a prodotti con mercato anche nei paesi ricchi |
| Governance | Forte influenza di Gates Foundation su priorita' |

---

## Fonti

### Ufficiali
- [GHIC - Global Health Investment Fund](https://ghicfunds.org/global-health-investment-fund/)
- [GHIC - About](https://ghicfunds.org/about/)
- [Gates Foundation SIF - GHIF](https://sif.gatesfoundation.org/investments/ghif/)

### Analisi
- [World Bank - GHIF Case Study](https://documents.worldbank.org/en/publication/documents-reports/documentdetail/959631487668386111)
- [Devex - GHIF Profile](https://www.devex.com/organizations/global-health-investment-fund-ghif-177316)

---

*Ultimo aggiornamento: Febbraio 2026*
